C J Rosenquist1, K K Lindfors. 1. Department of Radiology, University of California, Davis, School of Medicine, Sacramento 95817, USA.
Abstract
BACKGROUND: Several recent studies have added significant information regarding the benefit of screening mammography, especially in the 40-49-years age group. This new information makes it important to reassess the cost-effectiveness of screening. METHODS: A Markov model was used to study the cost-effectiveness of 4 age-related screening strategies: 1) annually from ages 40-79 years; 2) annually from ages 40-64 years and biennially from ages 65-79 years; 3) annually from ages 40-49 years and biennially from ages 50-79 years; and 4) annually from ages 40-79 years in high risk women (10%) and biennially from ages 40-49 years followed by annually from ages 50 -79 years in normal risk women (90%). An additional strategy simulating hormone status and estrogen exposure was evaluated. Cost-effectiveness was expressed as marginal cost per year-life saved (MCYLS). RESULTS: The MCYLS varied from $18,800 to $16,100. For all strategies this was within the range of other generally acceptable diagnostic and therapeutic medical procedures. There was a 14% decrease in MCYLS from the least cost-effective to the most cost-effective strategy. CONCLUSIONS: Cost-effectiveness of four age-related mammographic screening strategies was evaluated. The MCYLS for all strategies was within a generally accepted range. With increasing concerns regarding the cost of health care, this information may be useful in health policy decision-making.
BACKGROUND: Several recent studies have added significant information regarding the benefit of screening mammography, especially in the 40-49-years age group. This new information makes it important to reassess the cost-effectiveness of screening. METHODS: A Markov model was used to study the cost-effectiveness of 4 age-related screening strategies: 1) annually from ages 40-79 years; 2) annually from ages 40-64 years and biennially from ages 65-79 years; 3) annually from ages 40-49 years and biennially from ages 50-79 years; and 4) annually from ages 40-79 years in high risk women (10%) and biennially from ages 40-49 years followed by annually from ages 50 -79 years in normal risk women (90%). An additional strategy simulating hormone status and estrogen exposure was evaluated. Cost-effectiveness was expressed as marginal cost per year-life saved (MCYLS). RESULTS: The MCYLS varied from $18,800 to $16,100. For all strategies this was within the range of other generally acceptable diagnostic and therapeutic medical procedures. There was a 14% decrease in MCYLS from the least cost-effective to the most cost-effective strategy. CONCLUSIONS: Cost-effectiveness of four age-related mammographic screening strategies was evaluated. The MCYLS for all strategies was within a generally accepted range. With increasing concerns regarding the cost of health care, this information may be useful in health policy decision-making.
Authors: Natasha K Stout; Sandra J Lee; Clyde B Schechter; Karla Kerlikowske; Oguzhan Alagoz; Donald Berry; Diana S M Buist; Mucahit Cevik; Gary Chisholm; Harry J de Koning; Hui Huang; Rebecca A Hubbard; Diana L Miglioretti; Mark F Munsell; Amy Trentham-Dietz; Nicolien T van Ravesteyn; Anna N A Tosteson; Jeanne S Mandelblatt Journal: J Natl Cancer Inst Date: 2014-05-28 Impact factor: 13.506
Authors: Jerry Zeng Yang Wong; Jia Hui Chai; Yen Shing Yeoh; Nur Khaliesah Mohamed Riza; Jenny Liu; Yik-Ying Teo; Hwee Lin Wee; Mikael Hartman Journal: BMC Health Serv Res Date: 2021-04-23 Impact factor: 2.655